Circulating Tumor DNA (CtDNA) Methylation Market Report 2026

Circulating Tumor DNA (CtDNA) Methylation Market Overview

• Circulating Tumor DNA (CtDNA) Methylation market size has reached to $1.48 billion in 2025 • Expected to grow to $2.74 billion in 2030 at a compound annual growth rate (CAGR) of 13.1% • Growth Driver: Rise In Cancer Prevalence Driving The Growth Of The Market Due To Increasing Demand For Early Detection And Personalized Treatment • Market Trend: Early Cancer Detection Advancements Fueling ctDNA Methylation Market Growth • North America was the largest region in 2025.

What Is Covered Under Circulating Tumor DNA (CtDNA) Methylation Market?

Circulating tumor DNA (ctDNA) methylation refers to the addition of methyl groups to the DNA fragments released by tumor cells into the bloodstream. This epigenetic modification can affect gene expression and is often altered in cancer cells. Detecting ctDNA methylation patterns in blood allows for non-invasive cancer diagnosis, monitoring of tumor progression, and assessment of treatment response through liquid biopsy techniques. The main types of products in the circulating tumor DNA (ctDNA) methylation market are reagents and kits, instrumentations, software and bioinformatics solutions, and services. Reagents and kits refer to the consumable products used in circulating tumor DNA (ctDNA) methylation analysis, including materials for DNA extraction, bisulfite conversion, methylation detection, library preparation, and targeted enrichment. The various technologies include polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray, and other technologies. The types of samples include blood samples, urine samples, saliva samples, tissue samples, and other samples. The key applications include oncology, cardiovascular diseases, neurological disorders, infectious diseases, and others. The different end-users encompass hospitals and clinics, research laboratories, diagnostic laboratories, pharmaceutical and biotechnology companies, and academic institutions.

What Is The Circulating Tumor DNA (CtDNA) Methylation Market Growth Forecast?

The circulating tumor dna (ctdna) methylation market size is expected to see rapid growth in the next few years. It will grow to $2.74 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to development of targeted methylation panels, AI-enabled methylation analysis, early detection programs, growth of oncology research, expansion in emerging markets. Major trends in the forecast period include epigenetic biomarker analysis, integration with liquid biopsy, real-time tumor methylation monitoring, non-invasive cancer profiling, advanced ctdna methylation kits.

Global Circulating Tumor DNA (CtDNA) Methylation Market Segmentation

1) By Product Type: Reagents And Kits, Instrumentations, Software And Bioinformatics Solutions, Services 2) By Technology: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Microarray, Other Technologies 3) By Sample Type: Blood Samples, Urine Samples, Saliva Samples, Tissue Samples, Other Sample Types 4) By Application: Oncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Other Applications 5) By End-User: Hospitals And Clinics, Research Laboratories, Diagnostic Laboratories, Pharmaceutical And Biotechnology Companies, Academic Institutions Subsegments: 1) By Reagents And Kits: Cell Free DNA Extraction Kits, Bisulfite Conversion Kits, Methylation Detection Kits, Library Preparation Kits, Targeted Enrichment Kits 2) By Instrumentations: Sequencers, Real Time Polymerase Chain Reaction Systems, Digital Polymerase Chain Reaction Systems, Microarray Scanners, Droplet Digital Polymerase Chain Reaction Systems 3) By Software And Bioinformatics Solutions: Data Analysis Software, Methylation Pattern Interpretation Software, Genomic Visualization Tools, Pipeline Automation Software, Clinical Reporting Software 4) By Services: Sample Processing Services, Sequencing Services, Bioinformatics Analysis Services, Clinical Trial Support Services, Consultation And Training Services

What Is The Driver Of The Circulating Tumor DNA (CtDNA) Methylation Market?

The increasing prevalence of cancer is expected to drive the growth of the circulating tumor DNA (ctDNA) methylation market going forward. The prevalence of cancer is rising due to aging populations and lifestyle-related risk factors, including poor diet, smoking, and physical inactivity, which increase the risk of genetic mutations and tumor development. Circulating tumor DNA (ctDNA) methylation assays aid in early, non-invasive cancer detection, allow for accurate monitoring of disease progression, and help guide personalized treatment decisions, enabling timely and precise clinical interventions. For instance, in May 2024, according to the National Cancer Institute, a US-based government agency, the number of cancer survivors in the United States is expected to increase from 18.1 million in 2022 to 26 million by 2040. Therefore, the increasing prevalence of cancer is driving the growth of the ctDNA methylation market.

Key Players In The Global Circulating Tumor DNA (CtDNA) Methylation Market

Major companies operating in the circulating tumor dna (ctdna) methylation market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Exact Sciences Corporation, Qiagen N.V., Natera Inc., BGI Group, Guardant Health Inc., Invitae Corporation, Grail Inc., Genetron Holdings Limited, Buing Rock Biotech Limited, Zymo Research Corp, Agena Bioscience Inc., Phalanx Biotech Group Inc., Epigenomics Ag, EpigenDx Inc., Singlera Genomics Inc., Sampled

Global Circulating Tumor DNA (CtDNA) Methylation Market Trends and Insights

Major companies operating in the circulating tumor DNA (ctDNA) methylation market are focusing on developing multi-cancer early detection (MCED) blood tests that analyze cancer-specific methylation patterns in ctDNA, allowing for early, non-invasive detection of multiple cancer types. MCED tests help improve patient outcomes by detecting unique methylation signatures, enabling timely intervention and guiding more precise clinical decisions. For instance, in September 2025, Exact Sciences Corporation, a US-based molecular diagnostics company, launched Cancerguard, a multi-cancer early detection blood test integrating ctDNA methylation analysis. Cancerguard identifies unique methylation signatures across more than 50 cancer types, enabling highly sensitive and non-invasive detection, providing actionable insights for clinicians, and supporting ongoing monitoring and treatment decisions. This launch represents a significant step toward early intervention and improved survival rates through precision cancer care.

What Are Latest Mergers And Acquisitions In The Circulating Tumor DNA (CtDNA) Methylation Market?

In January 2023, Agilent Technologies Inc., a US-based company specializing in instruments, software, services, and consumables for laboratories, acquired Avida Biomed Inc. for an undisclosed amount. Through this acquisition, Agilent Technologies Inc. aims to integrate Avida Biomed Inc.’s target enrichment technologies to advance its precision oncology solutions and expand its leadership in molecular diagnostics. Avida Biomed is a US-based biotechnology company developing innovative circulating tumor DNA (ctDNA) methylation technologies for highly sensitive, non-invasive, and targeted early cancer detection.

Regional Outlook

North America was the largest region in the circulating tumor DNA (CtDNA) methylation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Circulating Tumor DNA (CtDNA) Methylation Market?

The circulating tumor DNA (ctDNA) methylation market consists of revenues earned by entities by providing services such as early cancer detection services, prognostic testing services, clinical trial support services, liquid biopsy services, and epigenetic profiling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The circulating tumor DNA (ctDNA) methylation market also includes sales of bisulfite conversion kits, methylation arrays, capillary electrophoresis systems, methyl-capture enrichment kits, and targeted methylation sequencing panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.